Oseltamivir capsules 75 mg No. 10

Oseltamivir is indicated for adults and children 1 year of age and older who have symptoms of influenza during influenza virus circulation. Efficacy has been demonstrated when treatment is initiated within 2 days of the first onset of symptoms.

Composition

active ingredient: oseltamivir;

1 capsule contains oseltamivir 75.00 mg in the form of oseltamivir phosphate 98.50 mg;

excipients: pregelatinized starch, talc, povidone K30, croscarmellose sodium, sodium stearyl fumarate;

capsule shell: titanium dioxide (E 171), iron oxide yellow (E 172), iron oxide red (E 172), gelatin, sodium lauryl sulfate.

Contraindication

Hypersensitivity to oseltamivir phosphate or to any component of the drug.

Method of application

For oral use.

Patients who cannot swallow a capsule can receive appropriate doses of Oseltamivir in the form of a powder for oral suspension.

Application features

Pregnant women

Pregnant women may use Oseltamivir, taking into account available safety information, the pathogenicity of the circulating influenza virus strain, and the condition of the pregnant woman after assessing the benefit/risk ratio.

Children

Used in children over 1 year of age with a body weight of more than 40 kg who are able to swallow the capsule.

Drivers

Does not affect.

Overdose

Reports of overdose with oseltamivir have been received during clinical trials and during post-marketing use of the drug. In the majority of reported cases of overdose, no adverse reactions were reported.

Adverse reactions reported in overdose were similar in nature and type to those observed with therapeutic doses of oseltamivir (see section "Adverse reactions").

There is no specific antidote.

Adverse reactions

Infections and infestations: common – bronchitis, herpes simplex, upper respiratory tract infections, nasopharyngitis, sinusitis;

Blood and lymphatic system disorders: rarely – thrombocytopenia;

Immune system disorders: uncommon – hypersensitivity reaction; rare – anaphylactic and anaphylactoid reactions;

Mental disorders: rarely common - agitation, abnormal behavior, anxiety, confusion, delusions, delirium, hallucinations, nightmares, self-harm.

Interaction

The pharmacokinetic properties of oseltamivir, such as low protein binding and metabolism independent of CYP450 and glucuronidase systems (see section 5.2), suggest that clinically significant interactions with other medicinal products are unlikely.

Storage conditions

Keep out of reach of children. Store in original packaging at a temperature not exceeding 25 ºС.

Shelf life: 4 years.